{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:05:57Z","timestamp":1790654757070,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-025-05989-y","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T11:25:40Z","timestamp":1758713140000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Methotrexate-induced pancytopenia: clinical characteristics, medication errors, and outcomes in a tertiary care centre: a retrospective single-centre study"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2000-7924","authenticated-orcid":false,"given":"Harshwardhan","family":"Patil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8134-8540","authenticated-orcid":false,"given":"Shiva","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7192-7271","authenticated-orcid":false,"given":"Ramaswamy","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7421-2418","authenticated-orcid":false,"given":"Mahabaleshwar","family":"Mamadapur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5227-0569","authenticated-orcid":false,"given":"R.","family":"Nikhil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3953-8903","authenticated-orcid":false,"given":"Acsah Annie","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"key":"5989_CR1","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/1756-185X.12862","volume":"19","author":"AN Malaviya","year":"2016","unstructured":"Malaviya AN (2016) Landmark papers on the discovery of methotrexate for the treatment of rheumatoid arthritis and other systemic inflammatory rheumatic diseases: a fascinating story. Int J Rheum Dis 19:844\u2013851. https:\/\/doi.org\/10.1111\/1756-185X.12862","journal-title":"Int J Rheum Dis"},{"key":"5989_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/rheumatology\/keh512","volume":"44","author":"AJ Kinder","year":"2005","unstructured":"Kinder AJ, Hassell AB, Brand J et al (2005) The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology (Oxford) 44:61\u201366. https:\/\/doi.org\/10.1093\/rheumatology\/keh512","journal-title":"Rheumatology (Oxford)"},{"key":"5989_CR3","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1136\/ard.2008.093690","volume":"68","author":"C Salliot","year":"2009","unstructured":"Salliot C, van der Heijde D (2009) Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 68:1100\u20131104. https:\/\/doi.org\/10.1136\/ard.2008.093690","journal-title":"Ann Rheum Dis"},{"key":"5989_CR4","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/bjd.15377","volume":"177","author":"C Mazaud","year":"2017","unstructured":"Mazaud C, Fardet L (2017) Relative risk of and determinants for adverse events of methotrexate prescribed at a low dose: a systematic review and meta-analysis of randomized placebo-controlled trials. Br J Dermatol 177:978\u2013986. https:\/\/doi.org\/10.1111\/bjd.15377","journal-title":"Br J Dermatol"},{"key":"5989_CR5","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1097\/MJT.0000000000000486","volume":"24","author":"A Mameli","year":"2017","unstructured":"Mameli A, Barcellona D, Marongiu F (2017) Fatal cytopenia induced by Low-Dose methotrexate in elderly with rheumatoid Arthritis. Identification of risk factors. Am J Ther 24:e106\u2013e107. https:\/\/doi.org\/10.1097\/MJT.0000000000000486","journal-title":"Am J Ther"},{"key":"5989_CR6","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jbspin.2018.07.004","volume":"86","author":"B Friedman","year":"2019","unstructured":"Friedman B, Cronstein B (2019) Methotrexate mechanism in treatment of rheumatoid arthritis. Joint Bone Spine 86:301\u2013307. https:\/\/doi.org\/10.1016\/j.jbspin.2018.07.004","journal-title":"Joint Bone Spine"},{"key":"5989_CR7","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1080\/03009740510018570","volume":"34","author":"T Kuitunen","year":"2005","unstructured":"Kuitunen T, Malmstr\u00f6m J, Palva E, Pettersson T (2005) Pancytopenia induced by low-dose methotrexate. A study of the cases reported to the Finnish adverse drug reaction register from 1991 to 1999. Scand J Rheumatol 34:238\u2013241. https:\/\/doi.org\/10.1080\/03009740510018570","journal-title":"Scand J Rheumatol"},{"key":"5989_CR8","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/1756-185X.13004","volume":"20","author":"S Ajmani","year":"2017","unstructured":"Ajmani S, Preet Singh Y, Prasad S et al (2017) Methotrexate-induced pancytopenia: a case series of 46 patients. Int J Rheum Dis 20:846\u2013851. https:\/\/doi.org\/10.1111\/1756-185X.13004","journal-title":"Int J Rheum Dis"},{"key":"5989_CR9","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s10067-006-0301-7","volume":"26","author":"Y Preet Singh","year":"2007","unstructured":"Preet Singh Y, Aggarwal A, Misra R, Agarwal V (2007) Low-dose methotrexate-induced pancytopenia. Clin Rheumatol 26:84\u201387. https:\/\/doi.org\/10.1007\/s10067-006-0301-7","journal-title":"Clin Rheumatol"},{"key":"5989_CR10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ejim.2019.07.016","volume":"67","author":"S Lalev\u00e9e","year":"2019","unstructured":"Lalev\u00e9e S, Lebrun-Vignes B, Simon C et al (2019) Cytopenia induced by low-dose methotrexate: an analysis of 433 cases from the French pharmacovigilance database. Eur J Intern Med 67:97\u2013101. https:\/\/doi.org\/10.1016\/j.ejim.2019.07.016","journal-title":"Eur J Intern Med"},{"key":"5989_CR11","unstructured":"Office of Drug Safety, Food and Drug Administration.Office of Drug Safety annual report FY 2001. Rockville (MD): Food and Drug Administration (2002) January"},{"key":"5989_CR12","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/art.1780390214","volume":"39","author":"S Gutierrez-Ure\u00f1a","year":"1996","unstructured":"Gutierrez-Ure\u00f1a S, Molina JF, Garc\u00eda CO et al (1996) Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum 39:272\u2013276. https:\/\/doi.org\/10.1002\/art.1780390214","journal-title":"Arthritis Rheum"},{"key":"5989_CR13","doi-asserted-by":"publisher","first-page":"384","DOI":"10.5694\/mja15.01242","volume":"204","author":"R Cairns","year":"2016","unstructured":"Cairns R, Brown JA, Lynch A-M et al (2016) A decade of Australian methotrexate dosing errors. Med J Aust 204:384. https:\/\/doi.org\/10.5694\/mja15.01242","journal-title":"Med J Aust"},{"key":"5989_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/09733698241229913","volume":"19","author":"P Mruthyunjaya","year":"2024","unstructured":"Mruthyunjaya P, Maikap D, Bhuyan B et al (2024) Clinical profile of acute methotrexate toxicity in rheumatic diseases: A series of 15 cases. Indian J Rheumatol 19:117\u2013122. https:\/\/doi.org\/10.1177\/09733698241229913","journal-title":"Indian J Rheumatol"},{"key":"5989_CR15","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1093\/ajhp\/61.13.1380","volume":"61","author":"TJ Moore","year":"2004","unstructured":"Moore TJ, Walsh CS, Cohen MR (2004) Reported medication errors associated with methotrexate. Am J Health Syst Pharm 61:1380\u20131384. https:\/\/doi.org\/10.1093\/ajhp\/61.13.1380","journal-title":"Am J Health Syst Pharm"},{"key":"5989_CR16","doi-asserted-by":"crossref","unstructured":"Liu S, Yuan Z, Rao S, Li W, Wu T, Deng S Adverse drug reactions related to methotrexate: a real-world pharmacovigilance study using the FAERS database from 2004 to 2024. Frontiers in Immunology [Internet]. 2025 June 4 [cited 2025 July 8];16. Availablefrom: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC12174053\/","DOI":"10.3389\/fimmu.2025.1586361"},{"key":"5989_CR17","doi-asserted-by":"publisher","unstructured":"Lev\u00eaque D, Santucci R, Gourieux B, Herbrecht R et al (2011) Pharmacokinetic drug-drug interactions with methotrexate in oncology. Expert Rev Clin Pharmacol 4:743\u2013750. https:\/\/doi.org\/10.1586\/ecp.11.57","DOI":"10.1586\/ecp.11.57"},{"issue":"1","key":"5989_CR18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13075-025-03551-6","volume":"27","author":"K Khoroshun","year":"2025","unstructured":"Khoroshun K, Bantel C, Hoffmann F, Jobski K (2025) Methotrexate-related drug reactions on kidneys and liver in rheumatoid arthritis: an analysis of spontaneous reports in eudravigilance. Arthritis Res Ther 27(1):80. https:\/\/doi.org\/10.1186\/s13075-025-03551-6. Published 2025 April 5","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"5989_CR19","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s10067-020-05363-2","volume":"40","author":"V Valerio","year":"2021","unstructured":"Valerio V, Kwok M, Loewen H et al (2021) Systematic review of recommendations on the use of methotrexate in rheumatoid arthritis. Clin Rheumatol 40(4):1259\u20131271. https:\/\/doi.org\/10.1007\/s10067-020-05363-2","journal-title":"Clin Rheumatol"},{"key":"5989_CR20","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/art.41752","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR et al (2021) 2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 73:1108\u20131123. https:\/\/doi.org\/10.1002\/art.41752","journal-title":"Arthritis Rheumatol"},{"key":"5989_CR21","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/1744666X.2017.1257939","volume":"13","author":"AB Maharaj","year":"2017","unstructured":"Maharaj AB, Chandran V (2017) Treatment of psoriatic arthritis with traditional dmard\u2019s and novel therapies: approaches and recommendations. Expert Rev Clin Immunol 13:319\u2013331. https:\/\/doi.org\/10.1080\/1744666X.2017.1257939","journal-title":"Expert Rev Clin Immunol"},{"key":"5989_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/bjd.14816","volume":"175","author":"RB Warren","year":"2016","unstructured":"Warren RB, Weatherhead SC, Smith CH et al (2016) British association of dermatologists\u2019 guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. Br J Dermatol 175:23\u201344. https:\/\/doi.org\/10.1111\/bjd.14816","journal-title":"Br J Dermatol"},{"key":"5989_CR23","doi-asserted-by":"publisher","first-page":"426","DOI":"10.2340\/00015555-2599","volume":"97","author":"L Raaby","year":"2017","unstructured":"Raaby L, Zachariae C, \u00d8stensen M et al (2017) Methotrexate use and monitoring in patients with psoriasis: A consensus report based on a Danish expert meeting. Acta Derm Venereol 97:426\u2013432. https:\/\/doi.org\/10.2340\/00015555-2599","journal-title":"Acta Derm Venereol"},{"key":"5989_CR24","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1111\/jdv.13354","volume":"29","author":"A Nast","year":"2015","unstructured":"Nast A, Gisondi P, Ormerod AD et al (2015) European S3-Guidelines on the systemic treatment of psoriasis vulgaris\u2013Update 2015\u2013Short version\u2013EDF in Cooperation with EADV and IPC. J Eur Acad Dermatol Venereol 29:2277\u20132294. https:\/\/doi.org\/10.1111\/jdv.13354","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5989_CR25","doi-asserted-by":"publisher","unstructured":"Rubio-Romero E, C\u00e9sar D\u00edaz-Torn\u00e9 (2024) Mar\u00eda Jos\u00e9 Moreno-Mart\u00ednez, Julen De-Luz. Methotrexate treatment strategies for rheumatoid arthritis: a scoping review on doses and administration routes. BMC Rheumatol 8(1) https:\/\/doi.org\/10.1016\/j.reumae.2020.08.009","DOI":"10.1016\/j.reumae.2020.08.009"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-025-05989-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-025-05989-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-025-05989-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:04:59Z","timestamp":1761847499000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-025-05989-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":25,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["5989"],"URL":"https:\/\/doi.org\/10.1007\/s00296-025-05989-y","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,24]]},"assertion":[{"value":"20 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Author Team has no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"235"}}